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ABSTRACT 
Background The long-term sequelae of coronavirus disease 2019 (Covid-19) in children 
remain poorly characterised. This study aimed to assess long-term outcomes in children 
previously hospitalised with Covid-19 and associated risk factors. 
Methods This is a prospective cohort study of children (≤18 years old) admitted with 
confirmed Covid-19. Children admitted to the hospital between April 2, 2020 and August 26, 
2020, were included. Telephone interview using the International Severe Acute Respiratory 
and emerging Infection Consortium (ISARIC) Covid-19 Health and Wellbeing paediatric 
follow-up survey. Persistent symptoms (>5 months) were further categorised by system(s) 
involved.  
 
Findings 518 of 853 (61%) of eligible children were available for the follow-up assessment 
and included in the study. Median age was 10.4 years (IQR, 3–15.2) and 270 (52.1%) were 
girls; median follow-up since hospital discharge was 256 (223-271) days. At the time of the 
follow-up interview 126 (24.3%) participants reported persistent symptoms among which 
fatigue (53, 10.7%), sleep disturbance (36, 6.9%,) and sensory problems (29, 5.6%) were the 
most common. Multiple symptoms were experienced by 44 (8.4%) participants. Risk factors 
for persistent symptoms were: older age “6-11 years” (odds ratio 2.74 (95% confidence 
interval 1.37 to 5.75) and “12-18 years” (2.68, 1.41 to 5.4); and a history of allergic diseases 
(1.67, 1.04 to 2.67). 
 
Interpretation A quarter of children experienced persistent symptoms months after 
hospitalization with acute covid-19 infection, with almost one in ten experiencing multi-
system involvement. Older age and allergic diseases were associated with higher risk of 
persistent symptoms at follow-up.  
  
INTRODUCTION 
Emerging data suggest that a substantial proportion of people experience ongoing symptoms 
including fatigue and muscle weakness, breathlessness, and neurological problems more 
than 6 months after the acute phase of Covid-19 [1, 2]. This phenomenon is commonly 
referred to as ‘long Covid’, a term defined by patient groups, and also known as post-Covid 
syndrome, the post-Covid-19 condition [3] or ‘Covid long-haulers [4, 5]. Recent population 
data from the UK reported that the highest prevalence of long Covid after 12 weeks was 
among those aged 25 to 34 years (18.2%) and lowest in the 2 to 11 years age bracket (7.4%) 
[6]. 
 
Evidence on post-acute covid condition and long term outcomes in children is still limited to 
small studies with more than half having at least one persisting symptom 4 months after 
covid-19 infection [7]. However, a recent publication from Australia suggested that only 8% 
of children aged 0-19 years (median 3 years) had ongoing symptoms 3-6 months after 
predominantly mild covid-19 infection. The limitation of the study as acknowledged by the 
authors was the low age range. This mandates the larger numbers inclusion particularly of 
older children in future studies [8]. 
 
There is a need to assess the long-term consequences of Covid-19 in paediatric populations 
[9], to inform clinicians, researchers and public health experts and address the impacts of 
this condition on those affected and their families and to inform discussions on vaccination 
of children. This cohort study aimed to investigate the incidence of and risk factors for long-
term Covid-19 outcomes in children post-hospital discharge. We used the standardised 
follow-up data collection protocol developed by the International Severe Acute Respiratory 




Study design, setting and participants 
This is a prospective cohort study of children (≤18 years old) admitted with suspected or 
confirmed Covid-19 to Z.A. Bashlyaeva Children’s Municipal Clinical Hospital in Moscow, 
Russia. This large tertiary university hospital can accommodate up to 980 children at a time 
and served as the primary Covid-19 hospital for children residing in Moscow city. Children 
admitted to the hospital during the first wave of the pandemic, between April 2, 2020 and 
August 26, 2020, with reverse transcriptase polymerase chain reaction (RT-PCR) confirmed 
SARS-CoV-2 infection were included. The parents of these children were contacted between 
January 31, 2021 and February 27, 2021 to complete a follow-up survey for this study. 
 
The acute-phase dataset included demographics, symptoms, co-morbidities, chest computer 
tomography (CT), supportive care, and clinical outcomes at discharge. This study was 
approved by the Moscow City Independent Ethics Committee (abbreviate 1, protocol number 
74). Parental consent was sought during hospital admission and consent for the follow-up 
interview was sought via verbal confirmation during telephone interview. 
 
Interviews were undertaken by a team of medical students with experience gained in 
previous Covid-19 research [2, 11] who underwent standardised training in telephone 
assessment, REDCap data entry and data security. Assessments were conducted via 
interviews with the parents/carers. Non-responders were contacted by telephone three times 
before considering them lost to follow-up. Information about the current condition and 
persisting symptoms was collected using the version 1.0 of the ISARIC COVID-19 Health and 
Wellbeing Follow-Up Survey for Children, to assess patients’ physical and psychosocial 
wellbeing and behaviour, with local adaptations (addition of questions related to 
signs/symptoms presence which symptom duration), translated into Russian. The protocol 
was registered at The Open Science Framework [12]. The follow-up survey documented data 
on demographics, parental perception of changes in their child’s emotional and behavioural 
status (including reasons for a change covid-19, pandemic or both), previous vaccination 
history, hospital stay and readmissions, mortality (after the initial index event), history of 
newly developed symptoms between discharge and the follow-up assessment, including 
symptom onset and duration, and overall health condition compared to prior to the child’s 
Covid-19 onset (Supplementary file). To assess the prevalence of symptoms over time 
parents were asked the following: (a) Within the last seven days, has your child had any of 
these symptoms, which were NOT present prior to their Covid-19 illness? (If yes, please 
indicate below and the duration of the symptom/s) and (b) Please report any symptoms 
that have been bothering your child since discharge that are not present today. Please 
specify the time of onset and duration of these symptoms. 
 
Data management  
REDCap electronic data capture tools (Vanderbilt University, Nashville, TN, USA) hosted at 
Sechenov University and Microsoft Excel (Microsoft Corp, Redmond, WA, USA) were used 
for data collection, storage and management [13, 14]. The baseline characteristics, including 
demographics, symptoms on admission and comorbidities were extracted from EMRs and 
entered into REDCap. 
Exposure and outcome variables 
For the purposes of this study, we defined “persistent symptoms” as symptoms present at the 
time of the follow-up interview and lasting for over 5 months. These were subcategorised 
into respiratory, neurological, sensory, sleep, gastrointestinal, dermatological, 
cardiovascular, fatigue and musculoskeletal (Table S1) informed by previously published 
literature [15, 16] and ISARIC Global Paediatric Covid-19 follow-up working group 
discussions. 
 
Allergic diseases were defined as a presence of any of the following: asthma, allergic rhinitis, 
eczema or food allergy. Participants age categories were based on Eunice Kennedy Shriver 
National Institute of Child Health and Human Development Pediatric Terminology [17]. 
Severe disease was defined as having received non-invasive ventilation, invasive ventilation 
or admission to the paediatric intensive care unit (PICU) during the hospital admission.  
 
Health status before Covid-19 and at the time of the interview was assessed using a 0 to 100 
wellness scale [18], where 0 was the worst possible health and 100 the best possible health. 
Statistical analysis 
Descriptive statistics were calculated for baseline characteristics. Continuous variables were 
summarised as median (with interquartile range) and categorical variables as frequency 
(percentage). The chi-squared test or Fisher’s exact test was used for testing hypotheses on 
differences in proportions between groups. The Wilcoxon rank-sum test was used for testing 
the hypotheses on differences between groups. 
 
We performed multivariable logistic regression to investigate associations of demographic 
characteristics, co-morbidities (limited to those reported in ≥5% of participants), presence of 
pneumonia during acute infection and severity of Covid-19 with persistent symptom 
categories presence at the time of the follow-up interview. We included all participants for 
whom the variables of interest were available in the final analysis, without imputing missing 
data. The differing denominators used indicate missing data. Odds ratios were calculated 
together with 95% confidence intervals (CIs).  
 
Upset plots were used to present the coexistence of persistent symptom categories. Two-
sided p-values were reported for all statistical tests, a p-value below 0.05 was considered to 
be statistically significant. Statistical analysis was performed using R version 3.5.1. Packages 
used included dplyr, lubridate, ggplots2, plotrix and UpSetR. 
 
Patient and public involvement 
The survey was developed by the ISARIC Global Paediatric Covid-19 follow-up working 
group and informed by a wide range of global stakeholders with expertise in infectious 
diseases, critical care, paediatrics, epidemiology, allergy-immunology, respiratory medicine, 
psychiatry, psychology and methodology and patient representatives. The survey was 




All 853 children hospitalised with suspected Сovid-19 to the hospital between April 2, 2020 
and August 26, 2020 were discharged alive (Figure 1). Of 836 patients with accurate 
contact information, parents of 518 RT-PCR positive children agreed to be interviewed 
(response rate 62%) and were included in the analysis.  
 
The median age was 10.4 years (IQR, 3-15.2; range, 2 days–18 years), 272 (52.2%) were girls. 
Median follow-up time since hospital admission was 268 days (IQR 233-284). Children had 
a median of 8 (IQR, 4-9) years of formal school education and a median of 4 (IQR, 3-5) 
family members were residing in the household (Table 1).  
 
The most common pre-existing comorbidity in this cohort was food allergy (13%, 67/514), 
followed by allergic rhinitis and asthma (9.7%, 50/514), gastrointestinal problems (9.3%, 
48/514), eczema (8.8%, 45/514) and neurological problems (8.4%, 43/514). Parents of 55.3% 
(284/514) children did not report any comorbidities. Fever (83.6%, 427/511), cough (55.7%, 
284/510), rhinorrhea (54.3%, 278/512) and fatigue (38.9%, 197/506) were the most 
common presenting symptoms at the time of the hospital admission (Table S2). 37.3%, 
192/515 of patients had pneumonia during hospital stay, 2.7%, 14/515 had severe disease, 
which required non-invasive ventilation/invasive ventilation or admission to PICU. 
Treatments received during the hospital admission are presented in Table S3. 
 
At the time of the follow-up interview, parents of 24.7% (128) children reported at least one 
persistent symptom, with fatigue 10.6% (53/496), insomnia 5.19% (26/501), disturbed smell 
4.7% (22/467) and headache 3.5% (17/486) being the most common. Detailed information 
on symptoms and duration is presented in Table S4. 
 
The prevalence of the symptoms present at the time of discharge declined over time (Figure 
2). Number of children with fatigue fell from 15.8% (82/518) at the time of discharge to 8.8% 
(45/513) 6-7 months later, altered sense of smell from 8.7% (45/518) to 4.7% (24/514), sleep 
disturbance 7.5% (39/518) to 5.8% (30/515), altered sense of taste from 5.6% (29/518) to 
3.1% (16/515), headache from 4.6% (24/518) to 3.5% (18/517), and breathing difficulties 
from 3.9% (20/518) to 1% (5/517), respectively. The prevalence of the most common 
symptoms including symptoms that developed some time after discharge are shown in 
Figure S1.  
 
With regard to persistent symptom categories (Table S1), fatigue was the most commonly 
reported in 10.6% (53/498) of patients at the time of assessment, followed by sleep 
disturbance 7.2% (36/501), sensory problems 6.2% (29/467), gastrointestinal 4.4% (22/499) 
and dermatological 3.6% (18/496) problems. A smaller number of patients experienced 
neurological 3% (14/465), respiratory 2.5% (12/489), cardiovascular 1.9% (9/470) and 
musculoskeletal 1.8% (9/489) problems long-term.  
 
A total of 8.5% (44) participants reported persistent symptoms from more than one category 
at the time of the follow-up assessment. Most commonly co-occurring categories were 
fatigue and sleep problems in 1.9% (10) of children, and fatigue and sensory problems were 
present in 1.5% (8) of participants. 2.7% (14) of children had persistent symptoms from three 
or more different categories. Co-existence of persistent symptom categories at the time of the 
follow-up is presented in the upset plot (Figure 3). 
 
The scores on the wellness scale for children with one or two or more persistent symptoms 
significantly declined when compared to before Covid-19 onset from 90 (80-100) to 82.5 
(70-93.8) and from 90 (80-95) to 70 (60-80) (p<0.001 for all comparisons), respectively. 
Children who did not experience any persistent symptoms did not report any significant 
changes in wellness when asked to compare to how they felt before their acute Covid-19 
illness. We also assessed emotional difficulties, social relationships, and activity levels in 
children (Tables S4 - S5). Parents related the following changes to Covid-19 illness, and not 
to the pandemic in general: less eating in 4.5% (23/512) of children, less sleeping in 3.5% 
(18/511) and more sleeping in 2% (10/511), reduced physical activity in 4.7% (24/512) and 
child becoming less emotional in 4.3% (22/511). In contrast, parents attributed changes to 
social activities to the pandemic in general rather than to the Covid-19 illness: 12% (58/485) 
of children were spending less time with their friends in person, while 13% (61/470) were 
spending more time with friends remotely, with less than one percent of parents attributing 
these changes to Covid-19 illness. 23% (110/478) of children were spending more time 
watching television, playing video/computer games or using social media for educational 
purposes, with 92.9% of parents associating these changes with the pandemic in general 
rather than the Covid-19 illness. 
 
In multivariable regression analysis, older age group was associated with persistent 
symptoms (Figure 4). When compared with children under two years of ages, those ages 6-
11 years had an odds ratio of 2.74 (95% confidence interval 1.37 to 5.75) of persistent 
symptoms and those 12-18 years of age (OR 2.68, 95% CI 1.41 to 5.4) both vs. <2 years. 
Another predictor associated with persistent symptoms was allergic diseases (OR 1.67, 95% 
CI 1.04 to 2.67). Similar patterns were seen for children with co-existence of persistent 
symptoms from 2 or more categories: 6-11 years of age (OR 2.49, 95% CI 1.02 to 6.72), 12-18 
years of age (OR 3.18, 95% CI 1.43 to 8.11) both vs. <2 years.  
 
We ran an additional regression analyses, using “age” as a continuous variable (Figure S2) 
which brought similar result. When subgroup analyses were performed in the age group of 
six years and above, severe acute Covid-19 was associated with persistent symptoms (OR 
6.14, 95% CI 1.27 to 43.94) and excessive weight and obesity with co-existence of persistent 
symptoms from 2 or more categories (OR 2.89, 95% CI 1.12 to 7.15) (Figure S3). 
 
DISCUSSION 
To our knowledge, this is the largest prospective paediatric cohort study with the longest 
follow-up, assessing symptom prevalence and duration of long COVID in children and 
adolescents with laboratory confirmed SARS-CoV-2 infection post hospital discharge. We 
found that a quarter of children and adolescents had persistent symptoms at the time of the 
follow-up with fatigue, sleep disturbance and sensory problems being the most common. 
Almost one in ten reported multi-system impacts with two or more categories of persistent 
symptoms at the time of the follow-up. Children in mid-childhood and adolescence (age 6-
18) were at higher risk of persistent symptoms at the time of the follow-up. Although 
prevalence of symptoms declined over time, a substantial proportion experienced problems 
many months after discharge. 
 
Although many children experienced symptoms, such as fatigue, disturbed smell and taste, 
sleep and respiratory problems, hair loss and headaches at the time of the hospital discharge, 
we witnessed a steady decline in the symptom prevalence over time. This was particularly 
evident for fatigue and smell disturbance. Prevalence of some symptoms such as headache, 
and sleep problems declined slower, which may be driven by psychological mechanisms 
rather than pathophysiologic virus infection effects [19]. A limitation of these findings is that 
symptom onset and duration was recalled at the single follow-up interview in our study; this 
may be overcome with repeated follow-ups at appropriate intervals to limit potential recall 
imprecision. There are very few studies assessing long COVID in children and adolescents; a 
previous smaller study from Italy found similar persisting symptoms during a shorter follow-
up [20]. In line with our results, previous research demonstrated symptoms fading over time 
in adults [15] but data are still limited as most of the published cohort studies do not 
measure symptom duration, but rather assess their presence at a single follow-up.  
 
We found that almost one in ten children had multisystem impacts with two or more 
categories of persistent symptoms present at the time of the follow-up. Similar numbers 
were previously reported in the Russian adult population [2] and patients with clusters of 
different symptoms were described in the UK [21]. Patients with multisystem involvement 
will represent the primary target for the future research and intervention strategies 
development. 
 
Age was significantly associated with persistent symptom presence at the time of the follow-
up, with children above 6 years of age being at higher risk. To our knowledge, risk factors for 
long Covid in children have not been investigated in previous studies, so we may draw 
comparisons with the data from adult cohorts only. Previous data suggest that long Covid is 
prevalent in adults [1, 2, 21-24] and that age is associated with a higher risk of long Covid 
[21, 23]. An Australian follow-up study of 151 children (median 3 years) who had 
predominantly mild acute covid-19 infection [8] found only 8% with on-going long-covid 
symptoms. As acknowledged by the authors the low median age may be the main reason for 
the low long-covid prevalence and our study substantiates this. We also found that in 
children of six years of age and above, severe acute Covid-19 was associated with persistent 
symptoms and excessive weight and obesity with multisystem involvement, but confidence 
intervals were wide and these findings require confirmation on a larger sample size to make 
any firm conclusions. 
 
We found that allergic diseases in children were also associated with a higher risk of long 
Covid. This is in agreement with adult studies from Russia [2] and the UK [21] reporting 
asthma to be associated with development of long Covid. Recent data suggested that COVID-
19 consequences may be linked with the mast cell activation syndrome [25] and the Th-2 
biased immunological response in children with allergic diseases may be responsible for an 
increased risk of long-term consequences from the infection. This highlights importance of 
further research of potential underlying immunological and autoimmune mechanisms of 
long Covid [26]. 
 
Apart from physical symptoms we assessed emotional and behavioural changes. Although 
most parents reported no changes, one in twenty parents noticed changes in their children, 
which they attributed to Covid-19 illness rather than the general situation during the 
pandemic. These included changes in eating, sleeping, emotional wellbeing and physical 
activities. Over one in ten parents noted that their children were spending less time in face-
to-face communication and more time interacting with their friends remotely and spending 
time online for both educational and non-educational purposes. These changes were largely 
attributed to the general situation during the pandemic rather than to the Covid-19 illness. 
The “lockdown” measures were implemented in Moscow in the middle of March and lasted 
until June 2020. Restrictions included self-isolation, public places closures, including 
schools/universities social distancing, etc. Pandemic resulted in increased anxiety levels 
among population, which was associated with increased media consumption [27]. The effect 
of pandemic, illness or both should be further studied in the future research. 
 
A major strength of this study is that it was based on the ISARIC COVID-19 Health and 
Wellbeing Follow-Up Survey for Children which will assist with data harmonisation and 
comparison with other international studies in the future. Another strength is the large 
sample size of confirmed Covid-19 infected children, and this cohort has the longest follow-
up assessment of hospitalised children to date. Stratification to determine if the symptoms 
were persistent following Covid-19 and assessment of trends over time were other novel 
aspects of the study. At the same time, this cohort study has several limitations. First, the 
study population only included patients within Moscow, although regional clustering is 
common to many cohort studies published during the Covid-19 pandemic. Second, it 
included only hospitalised children, not representative of paediatric population. Third, we 
did not have a control group of previously hospitalised children not experiencing Covid-19 
infection. Fourth, some patients may have developed additional comorbidities or 
complications since the hospital discharge, which were not appropriately captured and could 
potentially affect the wellbeing and symptom prevalence and persistence. Fifth, the 
parents/caregivers were interviewed in this study and not children themselves. There is also 
a risk of selection bias due to recruitment of the hospitalised population and recall bias in 
reporting symptoms which were non-existent at the time of the follow-up and potential 
selection bias with those with symptoms more likely to agree to survey. 
 
The study used to generate this data within the ISARIC WHO Clinical Characterisation 
Protocol initiative is a prospective pandemic preparedness protocol which is agnostic to 
disease and has a pragmatic design to allow recruitment during pandemic conditions. The 
reality of conducting research in outbreak conditions do not allow for appropriate co-
enrolment of a control group, which is not practical. One of the issues which has not been 
addressed so far in clinical research is what control group of individuals admitted to hospital 
during this period when hospitals were overwhelmed with Covid-19 cases could provide a 
valid control group. The design of this study allows only to describe the feature of Covid-19 
survivors and cannot involve a control group. Сovid-19 is not just a respiratory tract infection 
so there is no one-fit-all control group. At present, to our knowledge, all major publications 
on long Covid are uncontrolled cohorts due to the difficulties of ascertaining data among 
controls matched for age and sex but most importantly matched for the same experiences 
during the pandemic aside from confirmed Covid-19 illness.  
 
Our findings have implications for further research. Longer follow-up duration and repeated 
assessments combined with controls and sampling for further studies into the 
pathophysiology and immunology of post-Covid-19 illness sequelae are needed to inform 
case definitions, and intervention trials aimed to improve long term outcomes. 
 
Conclusion 
Although symptoms which were present at discharge diminished over time, even eight 
months after hospital discharge many children experienced persistent symptoms, with 
fatigue, sensory changes and sleep problems being the most common sequelae. One in ten 
children experienced multi-system involvement at the time of the follow-up. Age and allergic 
disease were the main risk factors for persistent symptoms. Future work should be 
multidisciplinary, prospective, preferably with a control cohort, repeated sampling and with 
an ability for children to report their health and wellbeing themselves, accompanied by 
biological sample collection to establish causative mechanisms for a better understanding of 
Covid-19 sequelae and help with the phenotype/endotype categorisation.  
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Figure 1. Flow diagram of patients with COVID-19 admitted to Z.A. Bashlyaeva Children’s Municipal 
Clinical Hospital between April 2, 2020 and August 26, 2020. “Other” includes relatives unable to 
describe child health; relatives not willing to refer interviewers to the child parents/carers; inability to 





Figure 2. Duration of the most common symptoms (post-discharge) in children who experienced symptoms at 
the time of discharge. The calculations are based on responses to the following questions: “Within the last seven 
days, has your child had any of these symptoms, which were NOT present prior to their Covid-19 illness? (If yes, 
please indicate below and the duration of the symptom/s) and “Please report any symptoms that have been 





Figure 3. Upset plot representing coexistence of the persistent symptom (present at the time of the follow-up 
interview and lasting for over 5 months) categories at the follow-up assessment. The values represent the number 
of individuals experiencing a persistent symptom category or combination of categories. Black lines link multiple 





Figure 4. Multivariable logistic regression model to identify pre-existing risk factors for post-COVID condition. 
Odds ratios and 95% CIs for presence of (A) any category of persistent symptoms (n=127) at the time of follow-up 
and (B) two or more co-existing categories of persistent symptoms (n=73) at the time of the follow-up. 






Sex, female 270/518 (52.1%) 




Age (categorical), years  
<2 105 (20.3%) 
2 – 5 80 (15.4%) 
6 – 11 113 (21.8%) 
12 – 18 220 (42.5%) 
Days from discharge to follow-up (median, IQR) 256 (223-271) 
Length of hospital admission (days, median, IQR) 10 (7-14) 
Number of years of formal school education (median, IQR) 8 (4-9) 
Number of members in household (median, IQR) 4 (3-5) 
Pneumonia during hospitalisation 192/515 (37.3%) 











Heart diseases 21/514 (4.1%) 
Haematological conditions 10/514 (1.9%) 
Tuberculosis 9/514 (1.8%) 













Other skin problems (not including eczema) 8/514 (1.6%) 
Gastrointestinal problems 48/514 (9.3%) 
Oncological conditions 3/514 (0.6%) 
Immune system diseases  6/514 (1.2%) 
Genetic conditions 6/514 (1.2%) 
Diabetes* 3/514 (0.6%) 
Other endocrine illness (not diabetes) 12/514 (2.3%) 
Renal/Kidney problems 18/514 (3.5%) 
Excessive weight and obesity 25/514 (4.9%) 
Malnutrition  10/514 (1.9%) 
Rheumatological conditions 4/514 (0.8%) 
Depression  4/514 (0.8%) 
Anxiety  5/514 (1%) 
HIV 0 (0%) 
No comorbidities  284/514 (55.3%) 
One comorbidity 141/514 (27.4%) 
Two comorbidities or more 89/514 (17.3%) 
Table 1. Demographic characteristics of patients admitted to the Z.A. Bashlyaeva Children’s Municipal Clinical 
Hospital. Data are n (%) or median (IQR) excluding missing values. *All cases of diabetes were type 1. †Allergic 
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Case Report Form (CRF) of Initial Survey: First Follow-Up Time Point version 1.0 
The questions were answered by the: 
□ Mother/female caregiver □ Father/male caregiver  
Date you completed the survey (DD/MM/YYYY): [_D_][_D_]/[_M_][_M_]/[_2_][_0_][_Y_][_Y_] 
What is your child’s date of birth (DD/MM/YYYY): [_D_][_D_]/[_M_][_M_]/[_Y_][_Y_][_Y_][_Y_] 
 
1. About your child  
Sex/Gender: □ Male □ Female □ Prefer not to say 
What is your child’s estimated height (cm): _______________ □ Not sure 
What is your child’s current estimated weight (kg): _________________□ Not sure  
What was your child's estimated weight before Covid19 illness (kg):                  □ Not sure  
How many other members regularly live in your household, including yourself: [_Number_]  
Does your child study in school/college/university? □ Yes □ No 
How many years formal school education has your child had?* [_Number_] 
*including primary school (e.g. from around 6 years depending on country)  
Does your child study in kindergarten? □ Yes □ No 
 
2. About your child’s Covid-19 illness - all the questions relate to his/her health and wellbeing) 
 
Approximately, what day did you first notice your child was experiencing symptoms of  
Covid-19? [_D_][_D_]/[_M_][_M_]/[_2_][_0_][_Y_][_Y_] 
How was your child diagnosed with Covid-19? 
□ Laboratory confirmed (positive PCR, antigen or Antibody test) □ Physician confirmed □ Test result is uncertain 
□ Not sure 
      Estimated date of your child’s most recent positive SARS-CoV-2 /Covid-19 test: 
[_D_][_D_]/[_M_][_M_]/[_2_][_0_][_2_][_Y_]   
Indicate if  □PCR test  □ Antibody test □ Unknown  
Has your child been admitted to hospital due to Covid-19? □ Yes □ No  
(If the answer is “no”, please, move on to the section “3”; if the answer is “yes”, please, proceed with the 
following questions) 
• Roughly at what date was your child first admitted to hospital? 
[_D_][_D_]/[_M_][_M_]/[_2_][_0_][_Y_][_Y_] 
• Roughly at what date was your child first discharged from hospital? 
[_D_][_D_]/[_M_][_M_]/[_2_][_0_][_Y_][_Y_] 
• If yes did they spent any time in the Paediatric Intensive Care Unit (PICU)? □ Yes □ No □ Not sure 
• Has your child been admitted to hospital after the first acute Covid-19 illness? □ Yes □ No 
If yes, how many times: [_Number_]   
Name of hospital/hospitals:                                                                                                              





3. About your child’s emotional wellbeing, social relationships and activities’ 
To answer the following questions, please mark an X on the lines below that shows your opinion on the question.  
A. Compared to before your child’s Covid-19 infection, how much is he/she now doing/experiencing the 
following  
If there are changes, please indicate whether you think these are due to the illness itself or to the Covid-19 pandemic 
   
Eating Sleeping 
 
□ Not known 
 
□ Not known 
   If there are changes, please indicate whether you think 
these are due to 
□ Illness itself □ Covid-19 pandemic □ Both □ Unsure 
If there are changes, please indicate whether you think these 
are due to 
□ Illness itself □ Covid-19 pandemic □ Both □ Unsure 
  
Physical Activity Fatigue 
 
□ Not known 
 
□ Not known 
     If there are changes, please indicate whether you think 
these are due to 
□ Illness itself □ Covid-19 pandemic □ Both □ Unsure 
If there are changes, please indicate whether you think  
these are due to 
□ Illness itself □ Covid-19 pandemic □ Both □ Unsure 
  
Spending time with friends in-person Spending time with friends remotely 
(e.g., online, social media, texting) 
 
□ Not known 
 
□ Not known 
     If there are changes, please indicate whether you think 
these are due to 
□ Illness itself □ Covid-19 pandemic □ Both □ Unsure 
If there are changes, please indicate whether you think  
these are due to 
□ Illness itself □ Covid-19 pandemic □ Both □ Unsure 
  
Spending time watching TV, playing                      
    video/computer games, or using                            
social media for educational purposes, including 
school/nursery work 
Spending time watching TV, playing                      
    video/computer games, or using                            
social media for non-educational purposes, 
 
□ Not known 
 
□ Not known 
     If there are changes, please indicate whether you think 
these are due to 
□ Illness itself □ Covid-19 pandemic □ Both □ Unsure 
If there are changes, please indicate whether you think 
 these are due to 










□ Not known 
 
□ My child has not been attending school/nursery before  
Covid-19 infection 
     If there are changes, please indicate whether you think 
these are due to 
□ Illness itself □ Covid-19 pandemic □ Both □ Unsure 
If there are changes, please indicate whether you think 
 these are due to 
□ Illness itself □ Covid-19 pandemic □ Both □ Unsure 
 
B. Compared to before your child’s Covid-19 illness: Have there been changes in your child’s… 
 





If there are changes, please indicate whether you think 
these are due to  
□ Illness itself □ Covid-19 pandemic □ Both □Unsure 
If there are changes, please indicate whether you think 
these are due to  
□ Illness itself □ Covid-19 pandemic □ Both □Unsure 
  





If there are changes, please indicate whether you think 
these are due to 
□ Illness itself □ Covid-19 pandemic □ Both □Unsure 
If there are changes, please indicate whether you think 
these are due to 
□ Illness itself □ Covid-19 pandemic □ Both □Unsure 
 
C. Have you asked for help from a health professional because of Covid-19 illness consequences to your 
child’s EMOTIONS, BEHAVIOUR OR RELATIONSHIPS?  
□ Yes □ No                 If yes who did you ask for help from_______________________________ 
 
 
D. If you have replied MUCH WORSE to any of the options in question “B” OR YOU HAVE ASKED FOR 
  HELP for these problems (question “C”), please, answer 3 of the following questions:  
 
          1. Do the difficulties upset or distress your child?  
          □ Not at all □ Only a little □ Undecided □ Quite a lot □ A great deal 
  






     3. Do these difficulties put a burden on you or the family as a whole?   
      □ Not at all □ Only a little □ Undecided □ Quite a lot □ A great deal □ Unsure 
 
E. Do you live in Moscow or Moscow Oblast?  □ Yes □ No 
If No,what is the current situation in your town/city/region on lockdown measures? 
Home Life □ Not at all □ Only a little □ Undecided □ Quite a lot □ A great deal   
Friendships □ Not at all □ Only a little □ Undecided □ Quite a lot □ A great deal   
Classroom Learning □ Not at all □ Only a little □ Undecided □ Quite a lot □ A great deal  




(you may select more than one answer) 
□ Closing of child’s school   □ Closing of nurseries/kindergartens 
□ Closing of non-essential shops (shops and stores apart 
from food, doctors and drug stores) 
□ Cancellation/closing of recreational venues and 
activities 
□ Closing of indoor places/venues □ Closing of outdoor recreational places 
□ Constraining meeting friends □ Stay-at-home orders (not allowed to leave the house 
except for essential errands) 
 
4a. About your child’s state of health prior to his/her Covid-19 illness 
Has your child been physician’s diagnosed or received treatment/support for any of the following chronic 
medical conditions prior to the Covid-19 infection? (answer with a tick in the box) 
 Yes No Unknown 
Prematurity (baby born <37 weeks)    
Neurological     
Neurodisability     
Heart diseases    
Respiratory diseases (not including asthma)    
Tuberculosis    
Asthma (doctor’s diagnosed)    
Allergic rhinitis/hay fever     
Food allergy    
Atopic dermatitis/Eczema    
Other skin problems (not including eczema)    
Gut problems    
Haematology (blood diseases)    
Oncology (cancer or other progressively enlarging or spreading tumor)    
Immune system diseases (e.g. primary immune deficiencies)    
Genetic conditions    
Diabetes (if yes indicate type: □ Type 1 □ Type 2)    
Other endocrine illness (not diabetes)    
Renal/Kidney problems    
Excessive weight and obesity    
Malnutrition (deficiencies, excesses, or imbalances in a person's 
intake of energy and/or nutrients) 
   
Rheumatology (e.g. arthritis, or inflammation of the joints)    
Depression     
Anxiety     
HIV    
Other (please indicate)  
 
 
Has your child ever been under Child and Adolescent Mental Health services before the Covid-19    
pandemic? □ Yes □ No □ Not sure 
 
Prior to Covid-19 infection, how was your child’s physical health in general? 
□ Very poor □ Poor □ Ok □ Good □ Very good  
If you ticked poor or very poor, please explain:  
 
Prior to Covid-19 infection, how would you describe your child’s mental health in general  
□ Very poor □ Poor □ Ok □ Good □ Very good  





Have you requested help because of Covid-19 consequences to your child’s physical health?  
         □ Yes □ No □ Not sure 
 4b. About your child’s current health 
    Has your child felt feverish recently? □ Yes □ No □ Not sure   
    If yes indicate when they felt feverish (tick all that apply)  
   □ Within the last 7 days □ >1-2 weeks □ >2-4 weeks □ >1-2 months □ >2-3 months □ >3-6 months  
 □ >6 months ago 
   If yes, what was the most likely cause of your child’s most recent feverish illness? 
 □ Covid-19 □ Other respiratory infection (cough/cold/sore throat) □ TB □ Stomach infection 
(diarrhea/vomiting) □ Urinary infection  □ Other (specify): ___________________________________ 
□ Unknown □ Prefer not to say            
If Covid-19, what was the estimated date of the most recent positive SARS-CoV-2 /Covid-19 test? 
[_D_][_D_]/[_M_][_M_]/[_2_][_0_][_2_][_Y_]   
Indicate if  □PCR test  □ Antibody test □ Unknown 
                                                       
 How much do you agree with the following statement?  
 “My child has fully recovered from Covid-19” 
Please mark an X on the line below that shows your opinion on the question as of TODAY 
 
5. Since having Covid-19, has your child been diagnosed with any of the following? (indicate the correct 
answer in the box provided) 
 YES NO  YES NO 
Multisystem inflammatory syndrome   Shock / Toxic shock syndrome   
Pulmonary embolism  
(PE, “Clot in lung”) 
  Coagulopathy 
(excessive bleeding or clotting) 
  
Kawasaki disease   Kidney problems   
Multisystem inflammatory syndrome 
(MIS-C/PIMS-TS) 
  Type 1 Diabetes   
Respiratory failure   Type 2 Diabetes   
Asthma   Intussusception   
 Myocarditis  
(inflammation of the heart muscle) 













6a. Within the last seven days, has your child had any of these symptoms, which were NOT present prior to their Covid-19 illness? 
If yes, please indicate below and the duration of the symptom/s: 
      
Respiratory problems Tick Yes or No  If yes, what is the duration of symptoms 
Nasal congestion / rhinorrhea □ Yes □ No □ < 1 month □ 1-2 months □ >2 -3 months □ >3-4 months □ >4-5 months 
□ >5-6 months □ >6-7 months □ >7 -8 months □ >8-9 months □ >9 -10 months 
□ >10-11 months □ >11 -12 months □ >12 months □ From the time of discharge 
□ Not sure 
Difficulty breathing /chest tightness □ Yes □ No □ < 1 month □ 1-2 months □ >2 -3 months □ >3-4 months □ >4-5 months 
□ >5-6 months □ >6-7 months □ >7 -8 months □ >8-9 months □ >9 -10 months 
□ >10-11 months □ >11 -12 months □ >12 months □ From the time of discharge 
□ Not sure 
Pain on breathing □ Yes □ No □ < 1 month □ 1-2 months □ >2 -3 months □ >3-4 months □ >4-5 months 
□ >5-6 months □ >6-7 months □ >7 -8 months □ >8-9 months □ >9 -10 months 
□ >10-11 months □ >11 -12 months □ >12 months □ From the time of discharge 
□ Not sure 
Chest pain □ Yes □ No □ < 1 month □ 1-2 months □ >2 -3 months □ >3-4 months □ >4-5 months 
□ >5-6 months □ >6-7 months □ >7 -8 months □ >8-9 months □ >9 -10 months 
□ >10-11 months □ >11 -12 months □ >12 months □ From the time of discharge 
□ Not sure 
Persistent cough □ Yes □ No □ < 1 month □ 1-2 months □ >2 -3 months □ >3-4 months □ >4-5 months 
□ >5-6 months □ >6-7 months □ >7 -8 months □ >8-9 months □ >9 -10 months 
□ >10-11 months □ >11 -12 months □ >12 months □ From the time of discharge 
□ Not sure 
If yes, □ dry cough □ with phlegm 
Musculoskeletal problems Tick Yes or No If yes, what is the duration of symptoms 
Cannot fully move or control movement □ Yes □ No □ < 1 month □ 1-2 months □ >2 -3 months □ >3-4 months □ >4-5 months 
□ >5-6 months □ >6-7 months □ >7 -8 months □ >8-9 months □ >9 -10 months 
□ >10-11 months □ >11 -12 months □ >12 months □ From the time of discharge 
□ Not sure 
Problems with balance □ Yes □ No □ < 1 month □ 1-2 months □ >2 -3 months □ >3-4 months □ >4-5 months 
□ >5-6 months □ >6-7 months □ >7 -8 months □ >8-9 months □ >9 -10 months 
□ >10-11 months □ >11 -12 months □ >12 months □ From the time of discharge 
□ Not sure 
Persistent muscle pain □ Yes □ No □ < 1 month □ 1-2 months □ >2 -3 months □ >3-4 months □ >4-5 months 
□ >5-6 months □ >6-7 months □ >7 -8 months □ >8-9 months □ >9 -10 months 
□ >10-11 months □ >11 -12 months □ >12 months □ From the time of discharge 




Joint pain or swelling □ Yes □ No □ < 1 month □ 1-2 months □ >2 -3 months □ >3-4 months □ >4-5 months 
□ >5-6 months □ >6-7 months □ >7 -8 months □ >8-9 months □ >9 -10 months 
□ >10-11 months □ >11 -12 months □ >12 months □ From the time of discharge 
□ Not sure 
Neurological problems Tick Yes or No If yes, what is the duration of symptoms 
Headache  □ Yes □ No □ < 1 month □ 1-2 months □ >2 -3 months □ >3-4 months □ >4-5 months 
□ >5-6 months □ >6-7 months □ >7 -8 months □ >8-9 months □ >9 -10 months 
□ >10-11 months □ >11 -12 months □ >12 months □ From the time of discharge 
□ Not sure 
Dizziness/ light headedness □ Yes □ No □ < 1 month □ 1-2 months □ >2 -3 months □ >3-4 months □ >4-5 months 
□ >5-6 months □ >6-7 months □ >7 -8 months □ >8-9 months □ >9 -10 months 
□ >10-11 months □ >11 -12 months □ >12 months □ From the time of discharge 
□ Not sure 
Fainting/ blackouts □ Yes □ No □ < 1 month □ 1-2 months □ >2 -3 months □ >3-4 months □ >4-5 months 
□ >5-6 months □ >6-7 months □ >7 -8 months □ >8-9 months □ >9 -10 months 
□ >10-11 months □ >11 -12 months □ >12 months □ From the time of discharge 
□ Not sure 
Problems seeing/blurred vision □ Yes □ No □ < 1 month □ 1-2 months □ >2 -3 months □ >3-4 months □ >4-5 months 
□ >5-6 months □ >6-7 months □ >7 -8 months □ >8-9 months □ >9 -10 months 
□ >10-11 months □ >11 -12 months □ >12 months □ From the time of discharge 
□ Not sure 
Disturbed smell □ Yes □ No □ < 1 month □ 1-2 months □ >2 -3 months □ >3-4 months □ >4-5 months 
□ >5-6 months □ >6-7 months □ >7 -8 months □ >8-9 months □ >9 -10 months 
□ >10-11 months □ >11 -12 months □ >12 months □ From the time of discharge 
□ Not sure 
Loss of smell □ Yes □ No □ < 1 month □ 1-2 months □ >2 -3 months □ >3-4 months □ >4-5 months 
□ >5-6 months □ >6-7 months □ >7 -8 months □ >8-9 months □ >9 -10 months 
□ >10-11 months □ >11 -12 months □ >12 months □ From the time of discharge 
□ Not sure 
Disturbed taste □ Yes □ No □ < 1 month □ 1-2 months □ >2 -3 months □ >3-4 months □ >4-5 months 
□ >5-6 months □ >6-7 months □ >7 -8 months □ >8-9 months □ >9 -10 months 
□ >10-11 months □ >11 -12 months □ >12 months □ From the time of discharge 
□ Not sure 
Loss of taste □ Yes □ No □ < 1 month □ 1-2 months □ >2 -3 months □ >3-4 months □ >4-5 months 
□ >5-6 months □ >6-7 months □ >7 -8 months □ >8-9 months □ >9 -10 months 
□ >10-11 months □ >11 -12 months □ >12 months □ From the time of discharge 
□ Not sure 
Tremor/shakiness □ Yes □ No □ < 1 month □ 1-2 months □ >2 -3 months □ >3-4 months □ >4-5 months 
□ >5-6 months □ >6-7 months □ >7 -8 months □ >8-9 months □ >9 -10 months 
□ >10-11 months □ >11 -12 months □ >12 months □ From the time of discharge 
□ Not sure 
Tingling feeling/ “pins and needles“ □ Yes □ No □ < 1 month □ 1-2 months □ >2 -3 months □ >3-4 months □ >4-5 months 




□ >10-11 months □ >11 -12 months □ >12 months □ From the time of discharge 
□ Not sure 
Seizures/fits □ Yes □ No □ < 1 month □ 1-2 months □ >2 -3 months □ >3-4 months □ >4-5 months 
□ >5-6 months □ >6-7 months □ >7 -8 months □ >8-9 months □ >9 -10 months 
□ >10-11 months □ >11 -12 months □ >12 months □ From the time of discharge 
□ Not sure 
Confusion/lack of concentration □ Yes □ No □ < 1 month □ 1-2 months □ >2 -3 months □ >3-4 months □ >4-5 months 
□ >5-6 months □ >6-7 months □ >7 -8 months □ >8-9 months □ >9 -10 months 
□ >10-11 months □ >11 -12 months □ >12 months □ From the time of discharge 
□ Not sure 
Problems speaking or communicating □ Yes □ No □ < 1 month □ 1-2 months □ >2 -3 months □ >3-4 months □ >4-5 months 
□ >5-6 months □ >6-7 months □ >7 -8 months □ >8-9 months □ >9 -10 months 
□ >10-11 months □ >11 -12 months □ >12 months □ From the time of discharge 
□ Not sure 
Insomnia (hard to fall asleep, hard to stay asleep) □ Yes □ No □ < 1 month □ 1-2 months □ >2 -3 months □ >3-4 months □ >4-5 months 
□ >5-6 months □ >6-7 months □ >7 -8 months □ >8-9 months □ >9 -10 months 
□ >10-11 months □ >11 -12 months □ >12 months □ From the time of discharge 
□ Not sure 
Hypersomnia (excessive daytime sleepiness or 
prolonged nighttime sleep) 
□ Yes □ No □ < 1 month □ 1-2 months □ >2 -3 months □ >3-4 months □ >4-5 months 
□ >5-6 months □ >6-7 months □ >7 -8 months □ >8-9 months □ >9 -10 months 
□ >10-11 months □ >11 -12 months □ >12 months □ From the time of discharge 
□ Not sure 
Fatigue  □ Yes □ No □ < 1 month □ 1-2 months □ >2 -3 months □ >3-4 months □ >4-5 months 
□ >5-6 months □ >6-7 months □ >7 -8 months □ >8-9 months □ >9 -10 months 
□ >10-11 months □ >11 -12 months □ >12 months □ From the time of discharge 
□ Not sure 
Gastrointestinal problems Tick Yes or No If yes, what is the duration of symptoms 
Weight loss □ Yes □ No □ < 1 month □ 1-2 months □ >2 -3 months □ >3-4 months □ >4-5 months 
□ >5-6 months □ >6-7 months □ >7 -8 months □ >8-9 months □ >9 -10 months 
□ >10-11 months □ >11 -12 months □ >12 months □ From the time of discharge 
□ Not sure 
Problems swallowing or chewing □ Yes □ No □ < 1 month □ 1-2 months □ >2 -3 months □ >3-4 months □ >4-5 months 
□ >5-6 months □ >6-7 months □ >7 -8 months □ >8-9 months □ >9 -10 months 
□ >10-11 months □ >11 -12 months □ >12 months □ From the time of discharge 
□ Not sure 
Poor appetite □ Yes □ No □ < 1 month □ 1-2 months □ >2 -3 months □ >3-4 months □ >4-5 months 
□ >5-6 months □ >6-7 months □ >7 -8 months □ >8-9 months □ >9 -10 months 
□ >10-11 months □ >11 -12 months □ >12 months □ From the time of discharge 
□ Not sure 
Diarrhea □ Yes □ No □ < 1 month □ 1-2 months □ >2 -3 months □ >3-4 months □ >4-5 months 
□ >5-6 months □ >6-7 months □ >7 -8 months □ >8-9 months □ >9 -10 months 
□ >10-11 months □ >11 -12 months □ >12 months □ From the time of discharge 




Stomach/ abdominal pain □ Yes □ No □ < 1 month □ 1-2 months □ >2 -3 months □ >3-4 months □ >4-5 months 
□ >5-6 months □ >6-7 months □ >7 -8 months □ >8-9 months □ >9 -10 months 
□ >10-11 months □ >11 -12 months □ >12 months □ From the time of discharge 
□ Not sure 
Feeling nauseous  □ Yes □ No □ < 1 month □ 1-2 months □ >2 -3 months □ >3-4 months □ >4-5 months 
□ >5-6 months □ >6-7 months □ >7 -8 months □ >8-9 months □ >9 -10 months 
□ >10-11 months □ >11 -12 months □ >12 months □ From the time of discharge 
□ Not sure 
Vomiting □ Yes □ No □ < 1 month □ 1-2 months □ >2 -3 months □ >3-4 months □ >4-5 months 
□ >5-6 months □ >6-7 months □ >7 -8 months □ >8-9 months □ >9 -10 months 
□ >10-11 months □ >11 -12 months □ >12 months □ From the time of discharge 
□ Not sure 
Constipation □ Yes □ No □ < 1 month □ 1-2 months □ >2 -3 months □ >3-4 months □ >4-5 months 
□ >5-6 months □ >6-7 months □ >7 -8 months □ >8-9 months □ >9 -10 months 
□ >10-11 months □ >11 -12 months □ >12 months □ From the time of discharge 
□ Not sure 
Cardiovascular problems Tick Yes or No If yes, what is the duration of symptoms 
Palpitations (heart racing)  □ Yes □ No □ < 1 month □ 1-2 months □ >2 -3 months □ >3-4 months □ >4-5 months 
□ >5-6 months □ >6-7 months □ >7 -8 months □ >8-9 months □ >9 -10 months 
□ >10-11 months □ >11 -12 months □ >12 months □ From the time of discharge 
□ Not sure 
Variations in heart rate (tachycardia or 
bradycardia) 
□ Yes □ No □ < 1 month □ 1-2 months □ >2 -3 months □ >3-4 months □ >4-5 months 
□ >5-6 months □ >6-7 months □ >7 -8 months □ >8-9 months □ >9 -10 months 
□ >10-11 months □ >11 -12 months □ >12 months □ From the time of discharge 
□ Not sure 
Bleeding □ Yes □ No □ < 1 month □ 1-2 months □ >2 -3 months □ >3-4 months □ >4-5 months 
□ >5-6 months □ >6-7 months □ >7 -8 months □ >8-9 months □ >9 -10 months 
□ >10-11 months □ >11 -12 months □ >12 months □ From the time of discharge 
□ Not sure 
If yes, specify bleeding site:   
Genitourinary problems  Tick Yes or No If yes, what is the duration of symptoms  If yes, what is the duration of symptoms 
Urination problems □ Yes □ No □ < 1 month □ 1-2 months □ >2 -3 months □ >3-4 months □ >4-5 months 
□ >5-6 months □ >6-7 months □ >7 -8 months □ >8-9 months □ >9 -10 months 
□ >10-11 months □ >11 -12 months □ >12 months □ From the time of discharge 
□ Not sure 
Changes in menstruation, (if regular before Covid-
19 illness) 
□ Yes □ No  
□ Not applicable 
□ < 1 month □ 1-2 months □ >2 -3 months □ >3-4 months □ >4-5 months 
□ >5-6 months □ >6-7 months □ >7 -8 months □ >8-9 months □ >9 -10 months 
□ >10-11 months □ >11 -12 months □ >12 months □ From the time of discharge 
□ Not sure 
Other problems Tick Yes or No If yes, what is the duration of symptoms 
Bilateral conjunctivitis 
If yes, □ purulent □ non-purulent 
□ Yes □ No □ < 1 month □ 1-2 months □ >2 -3 months □ >3-4 months □ >4-5 months 




□ >10-11 months □ >11 -12 months □ >12 months □ From the time of discharge 
□ Not sure 
Lumps or rashes (purple/pink) on toes □ Yes □ No □ < 1 month □ 1-2 months □ >2 -3 months □ >3-4 months □ >4-5 months 
□ >5-6 months □ >6-7 months □ >7 -8 months □ >8-9 months □ >9 -10 months 
□ >10-11 months □ >11 -12 months □ >12 months □ From the time of discharge 
□ Not sure 
Skin rash  □ Yes □ No □ < 1 month □ 1-2 months □ >2 -3 months □ >3-4 months □ >4-5 months 
□ >5-6 months □ >6-7 months □ >7 -8 months □ >8-9 months □ >9 -10 months 
□ >10-11 months □ >11 -12 months □ >12 months □ From the time of discharge 
□ Not sure 
Skin rash If yes, tick all body areas that apply: □ Yes □ No □ Face 






□ Accompanied by itch 
 
Hair loss □ Yes □ No □ < 1 month □ 1-2 months □ >2 -3 months □ >3-4 months □ >4-5 months 
□ >5-6 months □ >6-7 months □ >7 -8 months □ >8-9 months □ >9 -10 months 
□ >10-11 months □ >11 -12 months □ >12 months □ From the time of discharge 
□ Not sure 
Hyperhidrosis □ Yes □ No □ < 1 month □ 1-2 months □ >2 -3 months □ >3-4 months □ >4-5 months 
□ >5-6 months □ >6-7 months □ >7 -8 months □ >8-9 months □ >9 -10 months 
□ >10-11 months □ >11 -12 months □ >12 months □ From the time of discharge 
□ Not sure 
Other New Symptoms, if yes, specify all with their duration: If yes, what is the duration of symptoms 
 □ < 1 month □ 1-2 months □ >2 -3 months □ >3-4 months □ >4-5 months 
□ >5-6 months □ >6-7 months □ >7 -8 months □ >8-9 months □ >9 -10 months 
□ >10-11 months □ >11 -12 months □ >12 months □ From the time of discharge 
□ Not sure 
 □ < 1 month □ 1-2 months □ >2 -3 months □ >3-4 months □ >4-5 months 
□ >5-6 months □ >6-7 months □ >7 -8 months □ >8-9 months □ >9 -10 months 
□ >10-11 months □ >11 -12 months □ >12 months □ From the time of discharge 









6b. Please report any symptoms that have been bothering your child since discharge that are not present today. Please specify the time of onset 
and duration of these symptoms 
 
Respiratory problems Tick Yes or No  If yes, what was the time of onset 
Nasal congestion / rhinorrhea □ Yes □ No □ < 1 month □ 1-2 months □ >2 -3 months □ >3-4 months □ >4-5 months 
□ >5-6 months □ >6-7 months □ >7 -8 months □ >8-9 months □ >9 -10 months 
□ >10-11 months □ >11 -12 months □ >12 months □ From the time of discharge 
□ Not sure 
If yes, what was the duration of symptoms 
□ < 1 month □ 1-2 months □ >2 -3 months □ >3-4 months □ >4-5 months 
□ >5-6 months □ >6-7 months □ >7 -8 months □ >8-9 months □ >9 -10 months 
□ >10-11 months □ >11 -12 months □ >12 months □ Not sure 
Difficulty breathing /chest tightness □ Yes □ No If yes, what was the time of onset 
□ < 1 month □ 1-2 months □ >2 -3 months □ >3-4 months □ >4-5 months 
□ >5-6 months □ >6-7 months □ >7 -8 months □ >8-9 months □ >9 -10 months 
□ >10-11 months □ >11 -12 months □ >12 months □ From the time of discharge 
□ Not sure 
If yes, what was the duration of symptoms 
□ < 1 month □ 1-2 months □ >2 -3 months □ >3-4 months □ >4-5 months 
□ >5-6 months □ >6-7 months □ >7 -8 months □ >8-9 months □ >9 -10 months 
□ >10-11 months □ >11 -12 months □ >12 months □ Not sure 
Pain on breathing □ Yes □ No If yes, what was the time of onset 
□ < 1 month □ 1-2 months □ >2 -3 months □ >3-4 months □ >4-5 months 
□ >5-6 months □ >6-7 months □ >7 -8 months □ >8-9 months □ >9 -10 months 
□ >10-11 months □ >11 -12 months □ >12 months □ From the time of discharge 
□ Not sure 
If yes, what was the duration of symptoms 
□ < 1 month □ 1-2 months □ >2 -3 months □ >3-4 months □ >4-5 months 
□ >5-6 months □ >6-7 months □ >7 -8 months □ >8-9 months □ >9 -10 months 
□ >10-11 months □ >11 -12 months □ >12 months □ Not sure 
Chest pain □ Yes □ No If yes, what was the time of onset 
□ < 1 month □ 1-2 months □ >2 -3 months □ >3-4 months □ >4-5 months 
□ >5-6 months □ >6-7 months □ >7 -8 months □ >8-9 months □ >9 -10 months 
□ >10-11 months □ >11 -12 months □ >12 months □ From the time of discharge 
□ Not sure 
If yes, what was the duration of symptoms 
□ < 1 month □ 1-2 months □ >2 -3 months □ >3-4 months □ >4-5 months 
□ >5-6 months □ >6-7 months □ >7 -8 months □ >8-9 months □ >9 -10 months 
□ >10-11 months □ >11 -12 months □ >12 months □ Not sure 
Persistent cough □ Yes □ No If yes, what was the time of onset 
□ < 1 month □ 1-2 months □ >2 -3 months □ >3-4 months □ >4-5 months 




□ >10-11 months □ >11 -12 months □ >12 months □ From the time of discharge 
□ Not sure 
If yes, what was the duration of symptoms 
□ < 1 month □ 1-2 months □ >2 -3 months □ >3-4 months □ >4-5 months 
□ >5-6 months □ >6-7 months □ >7 -8 months □ >8-9 months □ >9 -10 months 
□ >10-11 months □ >11 -12 months □ >12 months □ Not sure 
If yes, □ dry cough □ with phlegm 
Musculoskeletal problems Tick Yes or No If yes, what was the time of onset 
Cannot fully move or control movement □ Yes □ No □ < 1 month □ 1-2 months □ >2 -3 months □ >3-4 months □ >4-5 months 
□ >5-6 months □ >6-7 months □ >7 -8 months □ >8-9 months □ >9 -10 months 
□ >10-11 months □ >11 -12 months □ >12 months □ From the time of discharge 
□ Not sure 
If yes, what was the duration of symptoms 
□ < 1 month □ 1-2 months □ >2 -3 months □ >3-4 months □ >4-5 months 
□ >5-6 months □ >6-7 months □ >7 -8 months □ >8-9 months □ >9 -10 months 
□ >10-11 months □ >11 -12 months □ >12 months □ Not sure 
Problems with balance □ Yes □ No If yes, what was the time of onset 
□ < 1 month □ 1-2 months □ >2 -3 months □ >3-4 months □ >4-5 months 
□ >5-6 months □ >6-7 months □ >7 -8 months □ >8-9 months □ >9 -10 months 
□ >10-11 months □ >11 -12 months □ >12 months □ From the time of discharge 
□ Not sure 
If yes, what was the duration of symptoms 
□ < 1 month □ 1-2 months □ >2 -3 months □ >3-4 months □ >4-5 months 
□ >5-6 months □ >6-7 months □ >7 -8 months □ >8-9 months □ >9 -10 months 
□ >10-11 months □ >11 -12 months □ >12 months □ Not sure 
Persistent muscle pain □ Yes □ No If yes, what was the time of onset 
□ < 1 month □ 1-2 months □ >2 -3 months □ >3-4 months □ >4-5 months 
□ >5-6 months □ >6-7 months □ >7 -8 months □ >8-9 months □ >9 -10 months 
□ >10-11 months □ >11 -12 months □ >12 months □ From the time of discharge 
□ Not sure 
If yes, what was the duration of symptoms 
□ < 1 month □ 1-2 months □ >2 -3 months □ >3-4 months □ >4-5 months 
□ >5-6 months □ >6-7 months □ >7 -8 months □ >8-9 months □ >9 -10 months 
□ >10-11 months □ >11 -12 months □ >12 months □ Not sure 
Joint pain or swelling □ Yes □ No If yes, what was the time of onset 
□ < 1 month □ 1-2 months □ >2 -3 months □ >3-4 months □ >4-5 months 
□ >5-6 months □ >6-7 months □ >7 -8 months □ >8-9 months □ >9 -10 months 
□ >10-11 months □ >11 -12 months □ >12 months □ From the time of discharge 
□ Not sure 
If yes, what was the duration of symptoms 
□ < 1 month □ 1-2 months □ >2 -3 months □ >3-4 months □ >4-5 months 
□ >5-6 months □ >6-7 months □ >7 -8 months □ >8-9 months □ >9 -10 months 




Neurological problems Tick Yes or No If yes, what was the time of onset 
Headache  □ Yes □ No □ < 1 month □ 1-2 months □ >2 -3 months □ >3-4 months □ >4-5 months 
□ >5-6 months □ >6-7 months □ >7 -8 months □ >8-9 months □ >9 -10 months 
□ >10-11 months □ >11 -12 months □ >12 months □ From the time of discharge 
□ Not sure 
If yes, what was the duration of symptoms 
□ < 1 month □ 1-2 months □ >2 -3 months □ >3-4 months □ >4-5 months 
□ >5-6 months □ >6-7 months □ >7 -8 months □ >8-9 months □ >9 -10 months 
□ >10-11 months □ >11 -12 months □ >12 months □ Not sure 
Dizziness/ light headedness □ Yes □ No If yes, what was the time of onset 
□ < 1 month □ 1-2 months □ >2 -3 months □ >3-4 months □ >4-5 months 
□ >5-6 months □ >6-7 months □ >7 -8 months □ >8-9 months □ >9 -10 months 
□ >10-11 months □ >11 -12 months □ >12 months □ From the time of discharge 
□ Not sure 
If yes, what was the duration of symptoms 
□ < 1 month □ 1-2 months □ >2 -3 months □ >3-4 months □ >4-5 months 
□ >5-6 months □ >6-7 months □ >7 -8 months □ >8-9 months □ >9 -10 months 
□ >10-11 months □ >11 -12 months □ >12 months □ Not sure 
Fainting/ blackouts □ Yes □ No If yes, what was the time of onset 
□ < 1 month □ 1-2 months □ >2 -3 months □ >3-4 months □ >4-5 months 
□ >5-6 months □ >6-7 months □ >7 -8 months □ >8-9 months □ >9 -10 months 
□ >10-11 months □ >11 -12 months □ >12 months □ From the time of discharge 
□ Not sure 
If yes, what was the duration of symptoms 
□ < 1 month □ 1-2 months □ >2 -3 months □ >3-4 months □ >4-5 months 
□ >5-6 months □ >6-7 months □ >7 -8 months □ >8-9 months □ >9 -10 months 
□ >10-11 months □ >11 -12 months □ >12 months □ Not sure 
Problems seeing/blurred vision □ Yes □ No If yes, what was the time of onset 
□ < 1 month □ 1-2 months □ >2 -3 months □ >3-4 months □ >4-5 months 
□ >5-6 months □ >6-7 months □ >7 -8 months □ >8-9 months □ >9 -10 months 
□ >10-11 months □ >11 -12 months □ >12 months □ From the time of discharge 
□ Not sure 
If yes, what was the duration of symptoms 
□ < 1 month □ 1-2 months □ >2 -3 months □ >3-4 months □ >4-5 months 
□ >5-6 months □ >6-7 months □ >7 -8 months □ >8-9 months □ >9 -10 months 
□ >10-11 months □ >11 -12 months □ >12 months □ Not sure 
Disturbed smell □ Yes □ No If yes, what was the time of onset 
□ < 1 month □ 1-2 months □ >2 -3 months □ >3-4 months □ >4-5 months 
□ >5-6 months □ >6-7 months □ >7 -8 months □ >8-9 months □ >9 -10 months 
□ >10-11 months □ >11 -12 months □ >12 months □ From the time of discharge 
□ Not sure 
If yes, what was the duration of symptoms 




□ >5-6 months □ >6-7 months □ >7 -8 months □ >8-9 months □ >9 -10 months 
□ >10-11 months □ >11 -12 months □ >12 months □ Not sure 
Loss of smell □ Yes □ No If yes, what was the time of onset 
□ < 1 month □ 1-2 months □ >2 -3 months □ >3-4 months □ >4-5 months 
□ >5-6 months □ >6-7 months □ >7 -8 months □ >8-9 months □ >9 -10 months 
□ >10-11 months □ >11 -12 months □ >12 months □ From the time of discharge 
□ Not sure 
If yes, what was the duration of symptoms 
□ < 1 month □ 1-2 months □ >2 -3 months □ >3-4 months □ >4-5 months 
□ >5-6 months □ >6-7 months □ >7 -8 months □ >8-9 months □ >9 -10 months 
□ >10-11 months □ >11 -12 months □ >12 months □ Not sure 
Disturbed taste □ Yes □ No If yes, what was the time of onset 
□ < 1 month □ 1-2 months □ >2 -3 months □ >3-4 months □ >4-5 months 
□ >5-6 months □ >6-7 months □ >7 -8 months □ >8-9 months □ >9 -10 months 
□ >10-11 months □ >11 -12 months □ >12 months □ From the time of discharge 
□ Not sure 
If yes, what was the duration of symptoms 
□ < 1 month □ 1-2 months □ >2 -3 months □ >3-4 months □ >4-5 months 
□ >5-6 months □ >6-7 months □ >7 -8 months □ >8-9 months □ >9 -10 months 
□ >10-11 months □ >11 -12 months □ >12 months □ Not sure 
Loss of taste □ Yes □ No If yes, what was the time of onset 
□ < 1 month □ 1-2 months □ >2 -3 months □ >3-4 months □ >4-5 months 
□ >5-6 months □ >6-7 months □ >7 -8 months □ >8-9 months □ >9 -10 months 
□ >10-11 months □ >11 -12 months □ >12 months □ From the time of discharge 
□ Not sure 
If yes, what was the duration of symptoms 
□ < 1 month □ 1-2 months □ >2 -3 months □ >3-4 months □ >4-5 months 
□ >5-6 months □ >6-7 months □ >7 -8 months □ >8-9 months □ >9 -10 months 
□ >10-11 months □ >11 -12 months □ >12 months □ Not sure 
Tremor/shakiness □ Yes □ No If yes, what was the time of onset 
□ < 1 month □ 1-2 months □ >2 -3 months □ >3-4 months □ >4-5 months 
□ >5-6 months □ >6-7 months □ >7 -8 months □ >8-9 months □ >9 -10 months 
□ >10-11 months □ >11 -12 months □ >12 months □ From the time of discharge 
□ Not sure 
If yes, what was the duration of symptoms 
□ < 1 month □ 1-2 months □ >2 -3 months □ >3-4 months □ >4-5 months 
□ >5-6 months □ >6-7 months □ >7 -8 months □ >8-9 months □ >9 -10 months 
□ >10-11 months □ >11 -12 months □ >12 months □ Not sure 
Tingling feeling/ “pins and needles“ □ Yes □ No If yes, what was the time of onset 
□ < 1 month □ 1-2 months □ >2 -3 months □ >3-4 months □ >4-5 months 
□ >5-6 months □ >6-7 months □ >7 -8 months □ >8-9 months □ >9 -10 months 
□ >10-11 months □ >11 -12 months □ >12 months □ From the time of discharge 




If yes, what was the duration of symptoms 
□ < 1 month □ 1-2 months □ >2 -3 months □ >3-4 months □ >4-5 months 
□ >5-6 months □ >6-7 months □ >7 -8 months □ >8-9 months □ >9 -10 months 
□ >10-11 months □ >11 -12 months □ >12 months □ Not sure 
Seizures/fits □ Yes □ No If yes, what was the time of onset 
□ < 1 month □ 1-2 months □ >2 -3 months □ >3-4 months □ >4-5 months 
□ >5-6 months □ >6-7 months □ >7 -8 months □ >8-9 months □ >9 -10 months 
□ >10-11 months □ >11 -12 months □ >12 months □ From the time of discharge 
□ Not sure 
If yes, what was the duration of symptoms 
□ < 1 month □ 1-2 months □ >2 -3 months □ >3-4 months □ >4-5 months 
□ >5-6 months □ >6-7 months □ >7 -8 months □ >8-9 months □ >9 -10 months 
□ >10-11 months □ >11 -12 months □ >12 months □ Not sure 
Confusion/lack of concentration □ Yes □ No If yes, what was the time of onset 
□ < 1 month □ 1-2 months □ >2 -3 months □ >3-4 months □ >4-5 months 
□ >5-6 months □ >6-7 months □ >7 -8 months □ >8-9 months □ >9 -10 months 
□ >10-11 months □ >11 -12 months □ >12 months □ From the time of discharge 
□ Not sure 
If yes, what was the duration of symptoms 
□ < 1 month □ 1-2 months □ >2 -3 months □ >3-4 months □ >4-5 months 
□ >5-6 months □ >6-7 months □ >7 -8 months □ >8-9 months □ >9 -10 months 
□ >10-11 months □ >11 -12 months □ >12 months □ Not sure 
Problems speaking or communicating □ Yes □ No If yes, what was the time of onset 
□ < 1 month □ 1-2 months □ >2 -3 months □ >3-4 months □ >4-5 months 
□ >5-6 months □ >6-7 months □ >7 -8 months □ >8-9 months □ >9 -10 months 
□ >10-11 months □ >11 -12 months □ >12 months □ From the time of discharge 
□ Not sure 
If yes, what was the duration of symptoms 
□ < 1 month □ 1-2 months □ >2 -3 months □ >3-4 months □ >4-5 months 
□ >5-6 months □ >6-7 months □ >7 -8 months □ >8-9 months □ >9 -10 months 
□ >10-11 months □ >11 -12 months □ >12 months □ Not sure 
Insomnia (hard to fall asleep, hard to stay asleep) □ Yes □ No If yes, what was the time of onset 
□ < 1 month □ 1-2 months □ >2 -3 months □ >3-4 months □ >4-5 months 
□ >5-6 months □ >6-7 months □ >7 -8 months □ >8-9 months □ >9 -10 months 
□ >10-11 months □ >11 -12 months □ >12 months □ From the time of discharge 
□ Not sure 
If yes, what was the duration of symptoms 
□ < 1 month □ 1-2 months □ >2 -3 months □ >3-4 months □ >4-5 months 
□ >5-6 months □ >6-7 months □ >7 -8 months □ >8-9 months □ >9 -10 months 
□ >10-11 months □ >11 -12 months □ >12 months □ Not sure 
Hypersomnia (excessive daytime sleepiness or 
prolonged nighttime sleep) 
□ Yes □ No If yes, what was the time of onset 
□ < 1 month □ 1-2 months □ >2 -3 months □ >3-4 months □ >4-5 months 




□ >10-11 months □ >11 -12 months □ >12 months □ From the time of discharge 
□ Not sure 
If yes, what was the duration of symptoms 
□ < 1 month □ 1-2 months □ >2 -3 months □ >3-4 months □ >4-5 months 
□ >5-6 months □ >6-7 months □ >7 -8 months □ >8-9 months □ >9 -10 months 
□ >10-11 months □ >11 -12 months □ >12 months □ Not sure 
Fatigue  □ Yes □ No If yes, what was the time of onset 
□ < 1 month □ 1-2 months □ >2 -3 months □ >3-4 months □ >4-5 months 
□ >5-6 months □ >6-7 months □ >7 -8 months □ >8-9 months □ >9 -10 months 
□ >10-11 months □ >11 -12 months □ >12 months □ From the time of discharge 
□ Not sure 
If yes, what was the duration of symptoms 
□ < 1 month □ 1-2 months □ >2 -3 months □ >3-4 months □ >4-5 months 
□ >5-6 months □ >6-7 months □ >7 -8 months □ >8-9 months □ >9 -10 months 
□ >10-11 months □ >11 -12 months □ >12 months □ Not sure 
Gastrointestinal problems Tick Yes or No If yes, what was the time of onset 
Weight loss □ Yes □ No □ < 1 month □ 1-2 months □ >2 -3 months □ >3-4 months □ >4-5 months 
□ >5-6 months □ >6-7 months □ >7 -8 months □ >8-9 months □ >9 -10 months 
□ >10-11 months □ >11 -12 months □ >12 months □ From the time of discharge 
□ Not sure 
If yes, what was the duration of symptoms 
□ < 1 month □ 1-2 months □ >2 -3 months □ >3-4 months □ >4-5 months 
□ >5-6 months □ >6-7 months □ >7 -8 months □ >8-9 months □ >9 -10 months 
□ >10-11 months □ >11 -12 months □ >12 months □ Not sure 
Problems swallowing or chewing □ Yes □ No If yes, what was the time of onset 
□ < 1 month □ 1-2 months □ >2 -3 months □ >3-4 months □ >4-5 months 
□ >5-6 months □ >6-7 months □ >7 -8 months □ >8-9 months □ >9 -10 months 
□ >10-11 months □ >11 -12 months □ >12 months □ From the time of discharge 
□ Not sure 
If yes, what was the duration of symptoms 
□ < 1 month □ 1-2 months □ >2 -3 months □ >3-4 months □ >4-5 months 
□ >5-6 months □ >6-7 months □ >7 -8 months □ >8-9 months □ >9 -10 months 
□ >10-11 months □ >11 -12 months □ >12 months □ Not sure 
Poor appetite □ Yes □ No If yes, what was the time of onset 
□ < 1 month □ 1-2 months □ >2 -3 months □ >3-4 months □ >4-5 months 
□ >5-6 months □ >6-7 months □ >7 -8 months □ >8-9 months □ >9 -10 months 
□ >10-11 months □ >11 -12 months □ >12 months □ From the time of discharge 
□ Not sure 
If yes, what was the duration of symptoms 
□ < 1 month □ 1-2 months □ >2 -3 months □ >3-4 months □ >4-5 months 
□ >5-6 months □ >6-7 months □ >7 -8 months □ >8-9 months □ >9 -10 months 




Diarrhea □ Yes □ No If yes, what was the time of onset 
□ < 1 month □ 1-2 months □ >2 -3 months □ >3-4 months □ >4-5 months 
□ >5-6 months □ >6-7 months □ >7 -8 months □ >8-9 months □ >9 -10 months 
□ >10-11 months □ >11 -12 months □ >12 months □ From the time of discharge 
□ Not sure 
If yes, what was the duration of symptoms 
□ < 1 month □ 1-2 months □ >2 -3 months □ >3-4 months □ >4-5 months 
□ >5-6 months □ >6-7 months □ >7 -8 months □ >8-9 months □ >9 -10 months 
□ >10-11 months □ >11 -12 months □ >12 months □ Not sure 
Stomach/ abdominal pain □ Yes □ No If yes, what was the time of onset 
□ < 1 month □ 1-2 months □ >2 -3 months □ >3-4 months □ >4-5 months 
□ >5-6 months □ >6-7 months □ >7 -8 months □ >8-9 months □ >9 -10 months 
□ >10-11 months □ >11 -12 months □ >12 months □ From the time of discharge 
□ Not sure 
If yes, what was the duration of symptoms 
□ < 1 month □ 1-2 months □ >2 -3 months □ >3-4 months □ >4-5 months 
□ >5-6 months □ >6-7 months □ >7 -8 months □ >8-9 months □ >9 -10 months 
□ >10-11 months □ >11 -12 months □ >12 months □ Not sure 
Feeling nauseous  □ Yes □ No If yes, what was the time of onset 
□ < 1 month □ 1-2 months □ >2 -3 months □ >3-4 months □ >4-5 months 
□ >5-6 months □ >6-7 months □ >7 -8 months □ >8-9 months □ >9 -10 months 
□ >10-11 months □ >11 -12 months □ >12 months □ From the time of discharge 
□ Not sure 
If yes, what was the duration of symptoms 
□ < 1 month □ 1-2 months □ >2 -3 months □ >3-4 months □ >4-5 months 
□ >5-6 months □ >6-7 months □ >7 -8 months □ >8-9 months □ >9 -10 months 
□ >10-11 months □ >11 -12 months □ >12 months □ Not sure 
Vomiting □ Yes □ No If yes, what was the time of onset 
□ < 1 month □ 1-2 months □ >2 -3 months □ >3-4 months □ >4-5 months 
□ >5-6 months □ >6-7 months □ >7 -8 months □ >8-9 months □ >9 -10 months 
□ >10-11 months □ >11 -12 months □ >12 months □ From the time of discharge 
□ Not sure 
If yes, what was the duration of symptoms 
□ < 1 month □ 1-2 months □ >2 -3 months □ >3-4 months □ >4-5 months 
□ >5-6 months □ >6-7 months □ >7 -8 months □ >8-9 months □ >9 -10 months 
□ >10-11 months □ >11 -12 months □ >12 months □ Not sure 
Constipation □ Yes □ No If yes, what was the time of onset 
□ < 1 month □ 1-2 months □ >2 -3 months □ >3-4 months □ >4-5 months 
□ >5-6 months □ >6-7 months □ >7 -8 months □ >8-9 months □ >9 -10 months 
□ >10-11 months □ >11 -12 months □ >12 months □ From the time of discharge 
□ Not sure 
If yes, what was the duration of symptoms 




□ >5-6 months □ >6-7 months □ >7 -8 months □ >8-9 months □ >9 -10 months 
□ >10-11 months □ >11 -12 months □ >12 months □ Not sure 
Cardiovascular problems Tick Yes or No If yes, what was the time of onset 
Palpitations (heart racing)  □ Yes □ No □ < 1 month □ 1-2 months □ >2 -3 months □ >3-4 months □ >4-5 months 
□ >5-6 months □ >6-7 months □ >7 -8 months □ >8-9 months □ >9 -10 months 
□ >10-11 months □ >11 -12 months □ >12 months □ From the time of discharge 
□ Not sure 
If yes, what was the duration of symptoms 
□ < 1 month □ 1-2 months □ >2 -3 months □ >3-4 months □ >4-5 months 
□ >5-6 months □ >6-7 months □ >7 -8 months □ >8-9 months □ >9 -10 months 
□ >10-11 months □ >11 -12 months □ >12 months □ Not sure 
Variations in heart rate (tachycardia or 
bradycardia) 
□ Yes □ No If yes, what was the time of onset 
□ < 1 month □ 1-2 months □ >2 -3 months □ >3-4 months □ >4-5 months 
□ >5-6 months □ >6-7 months □ >7 -8 months □ >8-9 months □ >9 -10 months 
□ >10-11 months □ >11 -12 months □ >12 months □ From the time of discharge 
□ Not sure 
If yes, what was the duration of symptoms 
□ < 1 month □ 1-2 months □ >2 -3 months □ >3-4 months □ >4-5 months 
□ >5-6 months □ >6-7 months □ >7 -8 months □ >8-9 months □ >9 -10 months 
□ >10-11 months □ >11 -12 months □ >12 months □ Not sure 
Bleeding □ Yes □ No If yes, what was the time of onset 
□ < 1 month □ 1-2 months □ >2 -3 months □ >3-4 months □ >4-5 months 
□ >5-6 months □ >6-7 months □ >7 -8 months □ >8-9 months □ >9 -10 months 
□ >10-11 months □ >11 -12 months □ >12 months □ From the time of discharge 
□ Not sure 
If yes, what was the duration of symptoms 
□ < 1 month □ 1-2 months □ >2 -3 months □ >3-4 months □ >4-5 months 
□ >5-6 months □ >6-7 months □ >7 -8 months □ >8-9 months □ >9 -10 months 
□ >10-11 months □ >11 -12 months □ >12 months □ Not sure 
If yes, specify bleeding site:   




□ Yes □ No 
 
□ < 1 month □ 1-2 months □ >2 -3 months □ >3-4 months □ >4-5 months 
□ >5-6 months □ >6-7 months □ >7 -8 months □ >8-9 months □ >9 -10 months 
□ >10-11 months □ >11 -12 months □ >12 months □ From the time of discharge 
□ Not sure 
If yes, what was the duration of symptoms 
□ < 1 month □ 1-2 months □ >2 -3 months □ >3-4 months □ >4-5 months 
□ >5-6 months □ >6-7 months □ >7 -8 months □ >8-9 months □ >9 -10 months 
□ >10-11 months □ >11 -12 months □ >12 months □ Not sure 
Changes in menstruation, (if regular before Covid-
19 illness) 
□ Yes □ No  
□ Not applicable 
If yes, what was the time of onset 




□ >5-6 months □ >6-7 months □ >7 -8 months □ >8-9 months □ >9 -10 months 
□ >10-11 months □ >11 -12 months □ >12 months □ From the time of discharge 
□ Not sure 
If yes, what was the duration of symptoms 
□ < 1 month □ 1-2 months □ >2 -3 months □ >3-4 months □ >4-5 months 
□ >5-6 months □ >6-7 months □ >7 -8 months □ >8-9 months □ >9 -10 months 
□ >10-11 months □ >11 -12 months □ >12 months □ Not sure 
Other problems Tick Yes or No If yes, what was the time of onset 
Bilateral conjunctivitis 
If yes, □ purulent □ non-purulent 
□ Yes □ No □ < 1 month □ 1-2 months □ >2 -3 months □ >3-4 months □ >4-5 months 
□ >5-6 months □ >6-7 months □ >7 -8 months □ >8-9 months □ >9 -10 months 
□ >10-11 months □ >11 -12 months □ >12 months □ From the time of discharge 
□ Not sure 
If yes, what was the duration of symptoms 
□ < 1 month □ 1-2 months □ >2 -3 months □ >3-4 months □ >4-5 months 
□ >5-6 months □ >6-7 months □ >7 -8 months □ >8-9 months □ >9 -10 months 
□ >10-11 months □ >11 -12 months □ >12 months □ Not sure 
Lumps or rashes (purple/pink) on toes □ Yes □ No If yes, what was the time of onset 
□ < 1 month □ 1-2 months □ >2 -3 months □ >3-4 months □ >4-5 months 
□ >5-6 months □ >6-7 months □ >7 -8 months □ >8-9 months □ >9 -10 months 
□ >10-11 months □ >11 -12 months □ >12 months □ From the time of discharge 
□ Not sure 
If yes, what was the duration of symptoms 
□ < 1 month □ 1-2 months □ >2 -3 months □ >3-4 months □ >4-5 months 
□ >5-6 months □ >6-7 months □ >7 -8 months □ >8-9 months □ >9 -10 months 
□ >10-11 months □ >11 -12 months □ >12 months □ Not sure 
Skin rash □ Yes □ No If yes, what was the time of onset 
□ < 1 month □ 1-2 months □ >2 -3 months □ >3-4 months □ >4-5 months 
□ >5-6 months □ >6-7 months □ >7 -8 months □ >8-9 months □ >9 -10 months 
□ >10-11 months □ >11 -12 months □ >12 months □ From the time of discharge 
□ Not sure 
If yes, what was the duration of symptoms 
□ < 1 month □ 1-2 months □ >2 -3 months □ >3-4 months □ >4-5 months 
□ >5-6 months □ >6-7 months □ >7 -8 months □ >8-9 months □ >9 -10 months 
□ >10-11 months □ >11 -12 months □ >12 months □ Not sure 
Skin rash If yes, tick all body areas that apply: □ Yes □ No □ Face 






□ Accompanied by itch 




□ < 1 month □ 1-2 months □ >2 -3 months □ >3-4 months □ >4-5 months 
□ >5-6 months □ >6-7 months □ >7 -8 months □ >8-9 months □ >9 -10 months 
□ >10-11 months □ >11 -12 months □ >12 months □ From the time of discharge 
□ Not sure 
If yes, what was the duration of symptoms 
□ < 1 month □ 1-2 months □ >2 -3 months □ >3-4 months □ >4-5 months 
□ >5-6 months □ >6-7 months □ >7 -8 months □ >8-9 months □ >9 -10 months 
□ >10-11 months □ >11 -12 months □ >12 months □ Not sure 
Hyperhidrosis □ Yes □ No If yes, what was the time of onset 
□ < 1 month □ 1-2 months □ >2 -3 months □ >3-4 months □ >4-5 months 
□ >5-6 months □ >6-7 months □ >7 -8 months □ >8-9 months □ >9 -10 months 
□ >10-11 months □ >11 -12 months □ >12 months □ From the time of discharge 
□ Not sure 
If yes, what was the duration of symptoms 
□ < 1 month □ 1-2 months □ >2 -3 months □ >3-4 months □ >4-5 months 
□ >5-6 months □ >6-7 months □ >7 -8 months □ >8-9 months □ >9 -10 months 
□ >10-11 months □ >11 -12 months □ >12 months □ Not sure 
Other New Symptoms, if yes, specify all with their onset and 
duration: 
If yes, what was the time of onset 
 □ < 1 month □ 1-2 months □ >2 -3 months □ >3-4 months □ >4-5 months 
□ >5-6 months □ >6-7 months □ >7 -8 months □ >8-9 months □ >9 -10 months 
□ >10-11 months □ >11 -12 months □ >12 months □ From the time of discharge 
□ Not sure 
If yes, what was the duration of symptoms 
□ < 1 month □ 1-2 months □ >2 -3 months □ >3-4 months □ >4-5 months 
□ >5-6 months □ >6-7 months □ >7 -8 months □ >8-9 months □ >9 -10 months 







7. Your child’s overall health status 
We would like to know how good or bad your child’s health was  
BEFORE Covid-19 and how it is TODAY  
 
This scale is numbered from 0 to 100%  
with 100% meaning the best health you can imagine  
0% means the worst health you can imagine. 
 
Please indicate on the scale and write the number in the box below each 
scale to indicate how good or bad your child’s health was BEFORE Covid-19 































































Has your child been vaccinated in accordance with the national vaccination schedule? 
  □ Yes, vaccinated up to date □ Yes, but some vaccines were missed □ No, I avoid vaccination for my child 
Please provide an approximate date of your child’s latest vaccination? 
[_D_][_D_]/[_M_][_M_]/[_2_][_0_][_Y_][_Y_] 
 Please, specify what was the vaccine: __________________□ I do not remember 
 I trust information I receive about vaccines? 
  □ Not at all □ Only a little □ Undecided □ Quite a lot □ A great deal    
 How confident are you in any of the childhood vaccines safety? 
   □ Not at all □ Only a little □ Undecided □ Quite a lot □ A great deal 
 Has your child been vaccinated against Covid-19?   □ Yes □ No □ Not sure 
 If yes, how many times have they had the Covid-19 vaccine?   [_Number_]   
           
         Estimated date of the last vaccine dose received: [_D_][_D_]/[_M_][_M_]/[_2_][_0_][_2_][_Y_] 
           
        Which type of Covid-19 vaccine did they receive:  AstraZeneca Pfizer-BioNTech   
       Imperial Janssens Moderna’s Sinopharm Sputnik V Other (name): ________ Not sure 
 If no, would you like to vaccinate your child against Covid-19 in the future? □ Yes □ No □ Not sure 
 I trust information I receive about Covid-19 vaccination?  
   □ Not at all □ Only a little □ Undecided □ Quite a lot □ A great deal 
 
 How confident are you in the safety of Covid-19 vaccinations?  
 □ Not at all □ Only a little □ Undecided □ Quite a lot □ A great deal     
  What is your opinion of Russian-made vaccines against Covid-19? 
□ Negative □ Neutral □ Positive □ Not sure 
What is your opinion of vaccines against Covid-19 produced abroad? 
□ Negative □ Neutral □ Positive □ Not sure 
 
9. Some questions about you 
      
During your child's illness, have you often been in a bad mood, depressed or feeling 
hopeless? 
□ Yes □ No 
During your child's illness, did you often feel that everything was difficult, and you did not 
want to do anything? 
□ Yes □ No 
During your child's illness, did you often feel persistent fatigue for no reason? □ Yes □ No 
Did your child's illness often make you feel nervous, anxious or extremely stressed? □ Yes □ No 
Did your child's illness often leave you unable to calm down or have you often been unable 
to calm or control your worries? 
□ Yes □ No 
Due to your child's illness, have you often experienced fear, as if something terrible were 
about to happen? 
□ Yes □ No 
Due to your child's illness, have you had to face aggressive or prejudiced attitudes from 
others? 
□ Yes □ No 




10. Please let us know of any further comments about the child’s illness, the pandemic, 














11. End of survey 





Table S1. Categorisation of persistent symptoms at follow-up.  
Symptom category Persistent symptoms included 
Musculoskeletal 
joint pain or swelling OR persistent muscle pain 
Cardiovascular variations in heart rate OR palpitations 
Respiratory difficulty breathing/chest tightness OR pain on breathing 
OR persistent cough 
Neurological cannot fully move or control movement OR problems with 
balance OR confusion/lack of concentration OR problems 
speaking or communicating OR seizures/fits OR tingling 
feeling/ ‘pins and needles’ OR tremor/shakiness OR 
dizziness/light headedness OR fainting/ blackouts 
Dermatological skin rash OR lumps or rashes (purple/pink) on toes OR  
hair loss 
Gastrointestinal constipation OR diarrhea OR feeling nauseous OR 
stomach/ abdominal pain OR vomiting 
Sensory disturbed smell OR disturbed taste OR loss of smell OR  
loss of taste 
Sleep hypersomnia OR insomnia 
Fatigue fatigue 
 
Table S2. Symptoms at the time of hospital admission.  
Characteristics Results 
History of fever 427/511 (83.6%) 
Cough 284/510 (55.7%) 
Fatigue 197/506 (38.9%) 
Rhinorrhoea 278/512 (54.3%) 
Shortness of breath  77/513 (15%) 
Disturbed smell or loss of smell 64/456 (14%) 
Sore throat 67/487 (13.8%) 
Lymphadenopathy 52/512 (10.2%) 
Headache 40/465 (8.6%) 
Diarrhoea 43/511 (8.4%) 
Skin rash 41/512 (8%) 
Wheezing 39/512 (7.6%) 
Vomiting / Nausea 32/512 (6.2%) 
Chest pain 28/464 (6%) 
Abdominal pain 27/489 (5.5%) 
Disturbed taste or Loss of taste 16/456 (3.5%) 
Muscle aches  14/463 (3%) 
Conjunctivitis 10/512 (2%) 
Joint pain 5/461 (1.1%) 
Ear pain 3/463 (0.6%) 
Seizures 3/512 (0.6%) 
Bleeding 3/512 (0.6%) 
Lower chest wall indrawing  3/512 (0.6%) 
Confusion 2/511 (0.4%) 
The differing denominators used indicate missing data. 
Table S3. Most commonly used treatments during the hospital stay. 
 
 
Characteristics Total  
Antiviral or COVID-19 targeted agent 394/512 (77.0%) 
Antibiotics 380/513 (74.1%) 
Mucolytics 188/513 (36.7%) 
Arbidol 133/512 (26%) 
Antifungal agent 25/513 (4.9%) 
Corticosteroid 20/513 (3.9%) 
Heparin 17/513 (3.3%) 
The differing denominators used indicate missing data. 
 
 







Total number of 
patients with the 
persistent 
symptom 
< 1  1-2  > 2-3  > 3-4  > 4-5   > 5-6   > 6-7  > 7-8  > 8-9  > 9-10   From the time 
of discharge 











































10/505 (1.98 %) 
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3/487 (0.62 %) 
Persistent muscle 
pain 
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The differing denominators used indicate missing data. 
Table S4. Parental perception of mood and behaviour changes in their children.  
Characteristic Likert scale response Reasons of changes 





Eating 14 (2.7%) 23 (4.5%) 445 (86.4%) 9 (1.7%) 10 (1.9%) 3 (0.6%) 11 (2.1%) 28 (49.1%) 4 (7%) 2 (3.5%) 23 (40.4%) 
Sleeping 15 (2.9%) 23 (4.5%) 447 (86.8%) 5 (1%) 11 (2.1%) 4 (0.8%) 10 (1.9%) 28 (52.8%) 7 (13.2%) 4 (7.5%) 14 (26.4%) 
Physical activity 27 (5.2%) 33 (6.4%) 429 (83.3%) 9 (1.7%) 4 (0.8%) 3 (0.6%) 10 (1.9%) 26 (37.7%) 22 (31.9%) 5 (7.2%) 16 (23.2%) 
Fatigue 3 (0.6%) 11 (2.1%) 400 (77.8%) 39 (7.6%) 48 (9.3%) 4 (0.8%) 9 (1.8%) 53 (53%) 11 (11%) 16 (16%) 20 (20%) 
Spending time with friends in-
person 
31 (6.2%) 27 (5.4%) 392 (78.1%) 19 (3.8%) 6 (1.2%) 17 (3.4%) 10 (2%) 4 (4.8%) 66 (78.6%) 7 (8.3%) 7 (8.3%) 
Spending time with friends remotely 1 (0.2%) 5 (1%) 397 (80.4%) 27 (5.5%) 37 (7.5%) 24 (4.9%) 3 (0.6%) 2 (2.8%) 58 (81.7%) 7 (9.9%) 4 (5.6%) 
Spending time watching TV, playing 
video/computer games, or using 
social media for educational 
purposes, including school/nursery 
work 
2 (0.4%) 2 (0.4%) 360 (71.9%) 42 (8.4%) 68 (13.6%) 23 (4.6%) 4 (0.8%) 2 (1.8%) 105 (92.9%) 2 (1.8%) 4 (3.5%) 
Spending time watching TV, playing 
video/computer games, or using 
social media for non-educational 
purposes 
4 (0.8%) 9 (1.8%) 408 (81.8%) 20 (4%) 28 (5.6%) 24 (4.8%) 6 (1.2%) 2 (3.4%) 44 (75.9%) 2 (3.4%) 10 (17.2%) 
Spending time outside 36 (7.1%) 39 (7.7%) 364 (71.5%) 35 (6.9%) 18 (3.5%) 6 (1.2%) 11 (2.2%) 5 (4.1%) 89 (73%) 11 (9%) 17 (13.9%) 
Attending school/nursery 29 (5.7%) 7 (1.4%) 313 (61.9%) 4 (0.8%) 36 (7.1%) 102 (20.2%) 15 (3%) 3 (3.7%) 65 (79.3%) 2 (2.4%) 12 (14.6%) 
Connectedness 4 (0.8%) 20 (4%) 456 (91%) 4 (0.8%) 1 (0.2%) 13 (2.6%) 3 (0.6%) 3 (10.7%) 14 (50%) 5 (17.9%) 6 (21.4%) 
Emotions 11 (2.2%) 57 (11.2%) 411 (80.4%) 11 (2.2%) 3 (0.6%) 5 (1%) 13 (2.5%) 24 (29.6%) 16 (19.8%) 10 (12.3%) 31 (38.3%) 
Behaviour 5 (1%) 37 (7.2%) 438 (85.5%) 8 (1.6%) 3 (0.6%) 5 (1%) 16 (3.1%) 16 (28.1%) 7 (12.3%) 6 (10.5%) 28 (49.1%) 
Relationships 1 (0.2%) 14 (2.8%) 481 (95.2%) 1 (0.2%) 0 (0%) 5 (1%) 3 (0.6%) 7 (46.7%) 2 (13.3%) 3 (20%) 3 (20%) 
The differing denominators used indicate missing data. 
 
 
Table S5. Parental-reported mood and behaviour changes due to Covid-19 and pandemic in their children, stratified by the the 
effect.  
Characteristic Caused by illness itself Caused by Covid-19 pandemic 
 Less More Less More 
















































Spending time watching TV, playing video/computer 
games, or using social media for educational purposes, 









Spending time watching TV, playing video/computer 































































Figure S1. The proportion of COVID-19 infected children who at various time points after discharge from hospital had one or 
more of the commonest continuing symptoms. Some children had more than one symptom. 
 
The prevalence was calculated based on responses to the following questions: “Within the last seven days, has your child had any 
of these symptoms, which were NOT present prior to their Covid-19 illness? (If yes, please indicate below and the duration of the 
symptom/s) and “Please report any symptoms that have been bothering your child since discharge that are not present today. 




Figure S2. Multivariable logistic regression model to identify pre-existing risk factors for post-COVID condition (using age as a 
continuous variable). Odds ratios and 95% CIs for presence of (A) any category of persistent symptoms at the time of follow-up 
and (B) two or more co-existing categories of persistent symptoms at the time of the follow-up. Neurological conditions include 









Figure S3. Multivariable logistic regression model to identify pre-existing risk factors for post-COVID condition (subgroup 
analyses in children ≥6 years of age). Odds ratios and 95% CIs for presence of (A) any category of persistent symptoms at the 
time of follow-up and (B) two or more co-existing categories of persistent symptoms at the time of the follow-up. Neurological 
conditions include “neurological disorders” and/or “neurodisability”. Abbreviation: CI, confidence interval. 
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